Prognositc Factors in COVID-19 Patients Complicated With Hypertension
Prognostic Characteristics Difference Between the Hypertension Patients With and Without ACEI Treatment When Suffered With 2019-nCoV Infection in China
調査の概要
状態
条件
詳細な説明
At present, the outbreak of the new coronavirus (2019-nCoV) infection in Wuhan and Hubei provinces has attracted great attention from the medical community across the country. Both 2019-nCoV and SARS viruses are coronaviruses, and they have a large homology.
Published laboratory studies have suggested that SARS virus infection and its lung injury are related to angiotensin-converting enzyme 2 (ACE2) in lung tissue. And ACE and ACE2 in the renin-angiotensin system (RAS) are vital central links to maintain hemodynamic stability and normal heart and kidney function in vivo.
A large amount of evidence-based medical evidence shows that ACE inhibitors are the basic therapeutic drugs for maintaining hypertension, reducing the risk of cardiovascular, cerebrovascular, and renal adverse events, improving quality of life, and prolonging life in patients with hypertension. Recent experimental studies suggest that treatment with ACE inhibitors can significantly reduce pulmonary inflammation and cytokine release caused by coronavirus infection.
研究の種類
連絡先と場所
研究場所
-
-
-
Chongqing、中国
- The First Affiliated Hospital of Chongqing Medical University
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
サンプリング方法
調査対象母集団
説明
Inclusion Criteria:
- Adult aged >=18years old;
- Diagnosed with 2019-nCoV. Diagnostic criteria including: Laboratory (RT-PCR) confirmed 2019-nCoV infection; CT of the lung conformed to the manifestation of viral pneumonia.
- Diagnosed with primary hypertension.
- Criteria for severe or critical ill conditions: Respiratory rate >=30/min; or Rest SPO2<=93%; or PaO2/FiO2<=300mmHg.
Exclusion Criteria:
- Near-death state (expected survival time less than 24 hours);
- Malignant tumor;
- Pregnancy or puerperium women;
- ACEI contraindication
- Patients who refused to participant.
研究計画
研究はどのように設計されていますか？
デザインの詳細
コホートと介入
グループ/コホート |
|---|
|
ACEI treatment
hypertension patients with ACEI treatment when suffered with novel coronavirus infection in China
|
|
Control
hypertension patients without ACEI treatment when suffered with novel coronavirus infection in China
|
この研究は何を測定していますか？
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Occupancy rate in the intensive care unit (ICU)
時間枠：up to 28 days
|
The percentage of patients admitted to the ICU at any time during the 28 days of onset COVID-19.
|
up to 28 days
|
|
Mechanical Ventilation
時間枠：up to 28 days
|
The number of patients requiring mechanical ventilation.
|
up to 28 days
|
|
Death
時間枠：up to 28 days
|
The number of patients who died of 2019-nCoV infection.
|
up to 28 days
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
All cause mortality
時間枠：up to 28 days
|
The number of died 2019-nCoV infected patients from any cause.
|
up to 28 days
|
|
Time from onset of symptoms to main outcome and its components
時間枠：up to 28 days
|
Time from onset of symptoms to admitted to the ICU, requiring mechanical ventilation, and death.
|
up to 28 days
|
|
Time to Clinical Recovery
時間枠：up to 28 days
|
Time to Clinical Recovery
|
up to 28 days
|
協力者と研究者
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (予想される)
研究の完了 (予想される)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。